RELATED CONTENT
NEWS
- Eisai plans EU filing for zonisamide first-line monotherapy
- Allos' Folotyn extends PFS and defers resistance to other drugs in lymphoma
- Positive Phase III data for LifeCycle's 'improved Prograf' despite higher drop-out
- Panel urges FDA to reject Novartis gouty arthritis drug on safety concerns

